EUVIMEDEUVIMED entdecken
Crossref

lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway

Yuzi Zhao, Li Hong

Cancer Biotherapy and Radiopharmaceuticals · 01.03.2021 · 36 (2) · 202-210

DOI: 10.1089/cbr.2019.3363 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biotherapy and Radiopharmaceuticals, erschienen am 01.03.2021. Verfasst von Yuzi Zhao und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynaecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan City, China. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, PhytogenicCell Line, TumorDrug Resistance, NeoplasmFemaleHumansMicroRNAsNF-kappa BNuclear ProteinsOvarian NeoplasmsPaclitaxelRNA, Long NoncodingSignal TransductionSurvival AnalysisTrans-Activators

Stichwörter der Autor:innen

RSF1/NF-κB signalinglncRNA-PRLBmiR-150-5povarian cancerpaclitaxel resistance

Substanzen

Antineoplastic Agents, PhytogenicMicroRNAsNF-kappa BNuclear ProteinsPaclitaxelRNA, Long NoncodingTrans-ActivatorsMIR150, humanRSF1 protein, human

Autor:innen und Institutionen

  • Department of Gynaecology and Obstetrics, Renmin Hospital of Wuhan University, Wuhan City, China.

Zitieren

APA

Zhao, Y., & Hong, L. (2021). lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway. Cancer Biotherapy and Radiopharmaceuticals, 36(2), 202-210. https://doi.org/10.1089/cbr.2019.3363

Vancouver

Zhao Y, Hong L. lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway. Cancer Biotherapy and Radiopharmaceuticals. 2021;36(2):202-210. doi:10.1089/cbr.2019.3363

BibTeX
@article{Zhao2021,
  author = {Zhao, Yuzi and Hong, Li},
  title = {lncRNA-PRLB Confers Paclitaxel Resistance of Ovarian Cancer Cells by Regulating RSF1/NF-κB Signaling Pathway},
  journal = {Cancer Biotherapy and Radiopharmaceuticals},
  year = {2021},
  volume = {36},
  number = {2},
  pages = {202--210},
  doi = {10.1089/cbr.2019.3363}
}
Kostenlos starten →